Cited by 22Liver Disease Diagnosis and TreatmentWnt/β-catenin signaling in development and cancerLiver physiology and pathology

Loss of Hepatic Leucine-Rich Repeat-Containing G-Protein Coupled Receptors 4 and 5 Promotes Nonalcoholic Fatty Liver Disease

Open access
Saponara, Enrica, Penno, Carlos, Orsini, Vanessa, Wang, Zhong-Yi, Fischer, Audrey, Aebi, Alexandra, Matadamas-Guzman, Meztli L., Brun, Virginie +25 more·2023·The American Journal of Pathology

Published version of a preprint

Abstract

Abstract Background & Aims The Rspo-Lgr4/5-Znrf3/Rnf43 module is a master regulator of hepatic Wnt/β-catenin signaling and metabolic zonation, but its impact on nonalcoholic fatty liver disease (NAFLD) remains unclear. We studied whether liver-specific loss of the Wnt/β-catenin modulators Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 4/5 (Lgr4/5) promotes nonalcoholic fatty liver disease (NAFLD). Methods Mice with liver-specific deletion of both receptors Lgr4/5 (Lgr4/5dLKO) were fed with normal diet (ND) or high fat diet (HFD). Livers of these mice were analyzed for lipid and fibrotic content by tissue staining and immunohistochemistry (IHC), and lipoproteins, inflammation and liver enzyme markers were measured in blood. Mechanistic insights into hepatic lipid accumulation were obtained by using ex vivo primary hepatocyte cultures derived from the Lgr4/5dLKO mice. Lipid analysis of mouse livers was performed by mass spectrometry (MS)-based untargeted lipidomic analysis. Results We demonstrated that liver-specific ablation of Lgr4/5-mediated Wnt signaling resulted in hepatic steatosis, impaired bile acid (BA) secretion and predisposition to liver fibrosis. Under HFD conditions, we observed progressive intrahepatic fat accumulation, developing into macro-vesicular steatosis. Serum lipoprotein levels in HFD-fed Lgr4/5dLKO mice were decreased, rather than increased, suggesting that accumulation of fat in the liver was due to impaired lipid secretion by hepatocytes. Our lipidome analysis revealed a severe alteration of several lipid species in livers of Lgr4/5dLKO mice, including triacylglycerol estolides (TG-EST), a storage form of bioactive free fatty acid (FA) esters of hydroxy FAs (FAHFAs). Conclusions Loss of hepatic Wnt/β-catenin activity by Lgr4/5 deletion led to deregulation of lipoprotein pathways, loss of BA secretion, intrinsic alterations of lipid homeostasis and the onset of NAFLD. Lay summary The Wnt/β-catenin pathway plays an important role during development and tissue homeostasis. Loss of Wnt/β-catenin activity in mouse liver leads to loss of liver zonation, but the impact on nonalcoholic fatty liver disease (NAFLD) remains unclear. We show that livers of mice developed steatosis upon deletion of the positive pathway regulators Lgr4/5. Livers of knock-out (KO) mice exhibited altered lipid composition due to impaired lipid secretion. Furthermore, livers of these mice developed a nonalcoholic steatohepatitis (NASH)-like phenotype and fibrotic features derived from activated hepatic stellate cells. Our data demonstrate a protective role of Wnt/β-catenin pathway activity towards the development of NAFLD. Highlights Abrogation of hepatic Wnt/β-catenin activity and liver zonation upon Lgr4/5 deletion in mice led to hepatic steatosis. Liver fat accumulation was caused by impaired lipid secretion from hepatocytes. Steatotic livers contained increased levels of diverse lipid species, including polyunsaturated fatty acids and triglycerol-estolides. These data confirmed that a decrease in Wnt/β-catenin signaling led to the development of nonalcoholic fatty liver disease (NAFLD) in mice.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajpath.2022.10.008

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • HSC-derived RSPO3, hepatocyte-expressed LGR4 and its downstream target β-catenin are central mediators of the HSC-hepatocyte cross-talk that controls liver size, zonation and function.

    “Thus, Rspo3ΔHSC mice reproduced key aspects of HSC-depleted, Lgr4/Lgr5ΔHep and Ctnnb1ΔHep mice24,25,34–39, suggesting HSC-derived RSPO3, hepatocyte-expressed LGR4 and its downstream target β-catenin as central mediators of the HSC–hepatocyte cross-talk that controls liver size, zonation and function.”

    From Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 (2025) · cites this paper as [39]

    The paper reports that Lgr4/5 deletion in hepatic epithelial cells compromises metabolic zonation and liver function, and links LGR4/5 to Wnt/β-catenin signaling (Introduction; Results, ‘Lgr4/5dLKO Mice Display Hepatic Lipid Accumulation’). It supports the Lgr4/Lgr5-deletion example in the citing sentence, but does not establish HSC-derived RSPO3 as the source of the signal or demonstrate the proposed HSC–hepatocyte cross-talk. Liver-size control appears in a cited reference rather than as a finding of this study. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • HSC-derived RSPO3 critically impacts liver size, zonation, metabolism, regeneration and injury.

    “The critical impact of HSC-derived RSPO3 on liver size, zonation, metabolism, regeneration and injury matches findings in mice with hepatocyte-specific deletion of β-catenin or LGR4/524,25,34–39, rendering RSPO3–LGR4-mediated HSC–hepatocyte communication a gatekeeper of liver function in health and disease.”

    From Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 (2025) · cites this paper as [39]

    The Lgr4/5dLKO Mice section reports compromised metabolic zonation and liver-regeneration potential after hepatic Lgr4/5 deletion; the paper also reports altered lipid metabolism and diet-dependent steatosis and fibrosis. These findings support the cited comparison, but the paper does not establish that HSC-derived RSPO3 itself causes the listed effects, including an effect on liver size. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • RSPO3 has seemingly opposing functions in acute toxic liver and chronic metabolic injury, aligning with the functions of its downstream target β-catenin in hepatocyte injury.

    “The seemingly opposing functions of RSPO3 in acute toxic liver and chronic metabolic injury align with the functions of its downstream target β-catenin in hepatocyte injury34–39.”

    From Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 (2025) · cites this paper as [39]

    The Introduction and Discussion (page unavailable in our copy) describe RSPO–LGR4/5 signaling upstream of β-catenin and report that impaired Wnt/β-catenin signaling promotes fatty liver disease in mice. They do not establish an opposing RSPO3 function in acute toxic liver injury or compare the two injury settings. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • RSPO3, LGR4/5 and their downstream target β-catenin protect against MASLD and ALD.

    “By contrast, MASLD and ALD, against which RSPO3, LGR4/5 and their downstream target β-catenin protect35,39, represent the commonest forms of CLD and liver fibrosis in patients.”

    From Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 (2025) · cites this paper as [39]

    The Discussion (page not supplied) reports that deleting hepatic Lgr4/5 in mice abolished Wnt/β-catenin activity and increased liver fat, inflammation, and predisposition to fibrosis, supporting a protective role against nonalcoholic fatty liver disease. The paper does not establish that RSPO3 itself protects against that disease, and the cited evidence does not address alcoholic liver disease (ALD). (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • β-catenin has roles in hepatic bile acid metabolism as well as mitochondrial function and energy balance, which have been linked to increased steatosis and liver injury in mice with hepatocellular deletion of β-catenin signalling components and in non-hepatic tissues.

    “These findings match the role of β-catenin in hepatic bile acid metabolism35,39,45 as well as mitochondrial function and energy balance37,38, which have been linked to increased steatosis and liver injury in mice with hepatocellular deletion of β-catenin signalling components35,37–39 and in non-hepatic tissues46,47.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 12

  1. Ma R, Martinez-Ramirez AS, Borders TL, Gao F, Sosa-Pineda B: Metabolic and non-metabolic liver zonation is established non- synchronously and requires sinusoidal Wnts. Elife 2020, 9:e46206
  2. Ruffner H, Sprunger J, Charlat O, Leighton-Davies J, Grosshans B, Salathe A, Zietzling S, Beck V, Therier M, Isken A, Xie Y, Zhang Y, Hao H, Shi X, Liu D, Song Q, Clay I, Hintzen G, Tchorz J, Bouchez LC, Michaud G, Finan P, Myer VE, Bouwmeester T, Porter J, Hild M, Bassilana F, Parker CN, Cong F: R-Spondin po- tentiates Wnt/beta-catenin signaling through orphan receptors LGR4 and LGR5. PLoS One 2012, 7:e40976
  3. Saponara E, Penno C, Matadamas-Guzmán ML, Brun V, Fischer B, Brousseau M, Wang ZY, ODonnell P, Turner J, Graff Meyer A, Bollepalli L, d'Ario G, Roma G, Carbone W, Orsini V, Annunziato S, Obrecht M, Beckmann N, Saravanan C, Osmont A, Tropberger P, Richards S, Genoud C, Aebi A, Ley S, Ksiazek I, Nigsch F, Terracciano L, Bouwmeester T, Tchorz JS, Ruffner H: Loss of he- patic Lgr4 and Lgr5 promotes nonalcoholic fatty liver disease. bio- Rxiv 2021, [Preprint] doi: 10.1101/2021.11.22.469602 · DOI
  4. De Livera AM, Olshansky G, Simpson JA, Creek DJ: Normal- izeMets: assessing, selecting and implementing statistical methods for normalizing metabolomics data. Metabolomics 2018, 14:54
  5. Griffett K, Bedia-Diaz G, Elgendy B, Burris TP: REV-ERB agonism improves liver pathology in a mouse model of NASH. PLoS One 2020, 15:e0236000
  6. Qiu B, Simon MC: BODIPY 493/503 staining of neutral lipid droplets for microscopy and quantification by flow cytometry. Bio Protoc 2016, 6:e1912
  7. Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N: Human organic anion transporter 1B1 and 1B3 function as bidirectional ajp.amjpathol.org -The American Journal of Pathology carriers and do not mediate GSH-bile acid cotransport. Am J Physiol Gastrointest Liver Physiol 2007, 293:G271eG278
  8. Lorbek G, Lewinska M, Rozman D: Cytochrome P450s in the syn- thesis of cholesterol and bile acids-from mouse models to human diseases. FEBS J 2012, 279:1516e1533
  9. Riecan M, Paluchova V, Lopes M, Brejchova K, Kuda O: Branched and linear fatty acid esters of hydroxy fatty acids (FAHFA) relevant to human health. Pharmacol Ther 2022, 231:107972
  10. Wang ZY, Keogh A, Waldt A, Cuttat R, Neri M, Zhu S, Schuierer S, Ruchti A, Crochemore C, Knehr J, Bastien J, Ksiazek I, Sanchez- Taltavull D, Ge H, Wu J, Roma G, Helliwell SB, Stroka D, Nigsch F: Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis. Sci Rep 2021, 11:19396
  11. Yang L, Wang J, Gong X, Fan Q, Yang X, Cui Y, Gao X, Li L, Sun X, Li Y, Wang Y: Emerging roles for LGR4 in organ develop- ment, energy metabolism and carcinogenesis. Front Genet 2021, 12: 728827
  12. Xie Y, Tian H, Xiang B, Li D, Liu J, Cai Z, Liu Y, Xiang H: Total polyunsaturated fatty acid intake and the risk of non-alcoholic fatty liver disease in Chinese Han adults: a secondary analysis based on a case-control study. BMC Gastroenterol 2021, 21:451

Cited by

Sorted by citations

Authors
Saponara, E., Penno, C., Orsini, V., Wang, Z.-Y., Fischer, A., Aebi, A., Matadamas-Guzman, M. L., Brun, V., Fischer, B., Brousseau, M., O'Donnell, P., Turner, J., Graff Meyer, A., Bollepalli, L., d’Ario, G., Roma, G., Carbone, W., Annunziato, S., Obrecht, M., Beckmann, N., Saravanan, C., Osmont, A., Tropberger, P., Richards, S. M., Genoud, C., Ley, S., Ksiazek, I., Nigsch, F., Terracciano, L. M., Schadt, H. S., Bouwmeester, T., Tchorz, J. S., & Ruffner, H.
Affiliations
  • Novartis (Switzerland) (CH)
  • National Institute of Genomic Medicine (MX)
  • University of Lausanne (CH)
  • Humanitas University (IT)
Corresponding author
Ruffner, Heinz
Venue
The American Journal of Pathology
Publisher
Elsevier BV
Published
2023-02
Volume
193
Issue
2
Pages
161-181
ISSN
0002-9440 (ISSN-L)
OpenAlex
W4309279525
Cited by
22
References
8
Citations by year
2026: 4 · 2025: 7 · 2024: 2 · 2023: 6 · 2022: 3
FWCI
3.25
Type
journal article
Language
en
Open access
Locations
  • American Journal Of Pathology (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • IRIS (submittedVersion)
  • The Novartis Repository (Novartis) (submittedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion)
Funders
Novartis Institutes for BioMedical Research Basel
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
non-alcoholic fatty liver disease, Wnt/β-catenin signaling, hepatic steatosis, liver fibrosis, bile acid secretion, cholestasis, hepatic lipid metabolism, high-fat diet, lipoprotein metabolism, hepatic zonation
MeSH terms
Animals, Cholesterol, Leucine, Liver, Mice, Inbred C57BL, Receptors, G-Protein-Coupled, beta Catenin, Mice, Diet, High-Fat, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review